Oncology
Pembrolizumab Just Lost a Head-to-Head Survival Fight
Ivonescimab significantly improved overall survival over pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC in HARMONi-2. A bispecific PD-1/VEGF antibody has now beaten one of oncology’s defining checkpoint inhibitors on both progression-free and overall survival.
Prostate Cancer Access Moves Into the Veterans System
Gastric Cancer Gets a New Biomarker Access Signal
Metastatic Cancer Means Living With Loss Before the End
Surviving Cancer Is Not the Same as Being Recovered
MRD Testing Moves From Prognosis Toward Treatment Action
Colon Cancer Immunotherapy Moves Into the Adjuvant Access Test
Cancer Is Chaos. Patients Should Not Have to Become Their Own Operating System
India’s emergency price-cap rise for cisplatin and carboplatin exposes a blunt oncology truth
G7 Cancer Call and WHA Precision Medicine Resolution: A Moment to Turn Ambition Into Delivery
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Oncology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases